The new area includes the recording of the webcast and the question and answer session, which took place on the 24th of November for interested parties, including shareholders. During the webcast, shareholders were given a more detailed presentation of the proposed merger with APIM and had the opportunity to ask specific questions about the merger plans.
Malene Brondberg, interim CEO and CFO of Nordic Nanovector, says: “We are delighted that so many shareholders watched yesterday’s webcast where we provided more information on the proposed merger with APIM Therapeutics. After a week of highly productive meetings between the Nordic Nanovector and APIM teams, our confidence in a company resulting from merger is even stronger than before. Our largest shareholder Folketrygdfondet confirms that it supports the Board’s proposal. We are confident that there is no better alternative and we encourage all shareholders to vote in favor of the proposed merger.”
The proposed merger, supported by the Boards of Directors of both companies, is the result of an extensive review conducted by Nordic Nanovector in conjunction with Carnegie Investment Bank (“Carnegie”) that explored a range of strategic options for the company. This review included careful evaluation of a possible stand-alone strategy for the Nordic Nanovector, which was deemed an unfeasible option by the Board.
After evaluating 25 potential merger and acquisition opportunities, the company has determined that the merger transaction with APIM represents the best and most exciting opportunity for all Nordic Nanovector shareholders, given, among other things, the significant and broad potential of the ATX -101, a novel anti-cancer peptide currently in Phase 2 trials. In addition, the combined company will have the discovery and development expertise to potentially generate several new drug candidates that add value from their technology platforms.
How to register for the General Assembly
Shareholders wishing to attend the general meeting must register by November 29, 2022 at 16:00 (CET). Shareholders may attend in person, by proxy or by prior vote. The deadline is the same for proxies and advance votes as for personal attendance. Until the deadline, votes already cast may be changed or withdrawn.
The electronic registration of attendance, proxies and early voting is easily available through the link published on the Company’s website: www.nordicnanovector.com. An individual reference does not. and the PIN code needed to access the service were sent to all shareholders with a known address.
Registration of personal attendance and powers of attorney can also be done by mail to Nordea Bank Abp, Norwegian Branch, Issuer Services, PO Box 1166 Sentrum, N-0107 Oslo, Norwayor email to: [email protected] within the time limit. No ref. not. and PIN code is required for registration by mail or email.
The attendance registration form (in person or by proxy) is attached to the notice available on the Nordic Nanovector website and on the company’s ticker at newsweb.no
Carnegie Investment Bank is acting as financial advisor to Nordic Nanovector. Advokatfirmaet Selmer AS is acting as legal counsel to Nordic Nanovector and KPMG AS has assisted Nordic Nanovector with financial due diligence and a fair opinion of the exchange ratio.
Advokatfirmaet Schjødt AS is acting as legal advisor to APIM. The APIM Therapeutics valuation was conducted by Venture Valuation AG, which has now agreed to be identified.
Jan H. Egberts, President of Nordic Nanovector
Malene Brondberg, Interim CEO and CFO of Nordic Nanovector
+44 7561 431 762
International Media – Frazer Hall / Mark Swallow (MEDiSTRAVA Consulting)
+44 203 928 6900
media in Norway 🇧🇷 Stein Jacob Fresco (Lilleby Fresh)
+47 916 10 911
About Nordic Nanovector
Nordic Nanovector is committed to developing and delivering innovative therapies to patients to address major unmet medical needs and advance cancer care. The company’s pipeline includes:
- Betalutin® and Humalutin®, both CD37-targeted radioimmunotherapies that incorporate the beta emitter lutetium-177 to treat non-Hodgkin’s lymphoma (NHL);
- Alpha37, a CD37-targeted radioimmunotherapy candidate incorporating the alpha-emitting radionuclide lead-212, currently being explored with partner Oranomed for chronic lymphocytic leukemia;
- Multiple fully humanized anti-CD37 antibodies with potential in hematological cancers and autoimmune diseases; and
- A CD37 DOTA CAR-T cell opportunity in hematologic cancers, which is being advanced through a research collaboration with the University of Pennsylvania🇧🇷
More information can be found at www.nordicnanovector.com.
This announcement is not and does not form part of any offer to sell or solicitation of an offer to buy any securities. Distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or shipped to any jurisdiction where such distribution is illegal or requires registration or other measures. Persons in whose possession this notice or other information is to come must inform themselves and observe such restrictions.
Matters discussed in this announcement constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as “believe”, “expect”, “anticipate”, “strategy”, “intend”, “estimate”, “will”, “may”, “continue “, “should” and similar expressions. The forward-looking statements in this release are based on
various assumptions, many of which are based, in turn, on other assumptions. While Nordic Nanovector believes these assumptions were reasonable when made, they are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and beyond its control.
The information, opinions and forward-looking statements contained in this announcement speak only as of the date of this announcement and are subject to change without notice. Nordic Nanovector undertakes no obligation to revise, update, confirm or publicly release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in connection with the content of this announcement.
This announcement is for informational purposes only and should not be considered a substitute for the exercise of independent judgment. It is not intended to be investment advice and under no circumstances should it be used or construed as an offer to sell or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities.
FONT Nordic Nanovector